Find in Library

APL also known as AML,M3 subtype is characterized by the typical morphology and t(15;17) translocation that fuses the PML gene on chromosome 15 to the RARA gene on chromosome 17, which serves as a “clone specific” molecular marker for the diagnosis and monitoring. ATRA, introduced in the early 1990s, has improved the outcome because of its unique differentiating action.  We report a patient in remission after chemotherapy for APL who developed AML, M2 subtype with no evidence of APL. This clinical syndrome though rare has been increasingly diagnosed and a subject of concern in few patients who are otherwise expected to have a good outcome.